EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma

Abstract Mantle cell lymphoma (MCL) is a relatively rare B‐cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely aggressive, related to the presence of biological risk factors such as proliferation rate and TP53 mutations. Most often, patients present with disseminated disease, necessitating systemic treatment. Immunochemotherapy has historically been the mainstay of treatment, but recent data indicate that addition of novel agents, especially covalent Bruton tyrosine kinase inhibitors (cBTKi), may substantially improve outcome in younger and older patients, although a curative approach remains to be shown. In elderly patients, the standard of care is still immuno‐chemotherapy such as rituximab‐bendamustine, although this may be challenged by non‐chemotherapeutic options, such as rituximab plus cBTKi. For patients with relapsed or refractory disease, treatment options are developing rapidly, including CAR‐T cell therapy, novel BTK targeting agents, BCL2 inhibitors, and T‐cell engagers. In this clinical practice guideline, we present current evidence‐based recommendations for diagnosis, staging, treatment, and follow‐up of MCL.